Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
This is a summary aggregated from CNBC. Read the complete article on the original site:
Read full article at CNBC
